STAT News, February 2, 2024: NCHR’s Diana Zuckerman’s commentary in STAT News explains why Medicare should not pay for every medical product that FDA approves, since some are more likely to harm rather than help Medicare patients. She points out that FDA does not require diversity in clinical trials and rarely includes enough older and less healthy patients that tend to rely on Medicare.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Deep flaws in FDA oversight of medical devices — and patient harm — exposed in lawsuits and records
CBS News, December 20, 2023: CBS News article dives into the lack of FDA oversight within the medical device industry. Increased patient harm is exposed in lawsuits and records.
Read More »FDA Warned of Overstepping Authority With Lab Test Rule Proposal
Bloomberg Law, December 7: Bloomberg Law news article describes the strong opposition to FDA’s plan to regulate lab-developed tests (LDTs). We explain why patients can’t trust the results of these diagnostic tests unless FDA makes sure they are accurate.
Read More »FDA’s Janet Woodcock to retire early next year
STAT News, November 16, 2023: Principal Deputy FDA Commissioner Janet Woodcock will retire from the FDA in early 2024 after almost 40 years at the agency, many as a powerful and controversial leader. We explain how her legacy has tarnished the FDA’s reputation.
Read More »After Drug Trial Fizzles, Sarepta Still Seeks Broad Approval
Bloomberg News, November 1, 2023: Sarepta’s gene therapy Elevidys failed to confirm efficacy for Duchenne Muscular Dystrophy. Will FDA convert accelerated approval to full approval anyway? We explain why that would be ridiculous, but not impossible. But who will pay for an unproven treatment that costs $3.2 million per patient?
Read More »